ABBV 10-K Annual Report Dec. 31, 2018 | Alphaminr
ALPHAMINR

ABBV 10-K Fiscal year ended Dec. 31, 2018

Balance Sheet
Cash Flow
Income Statement
ABBVIE INC.
10-Ks and 10-Qs
10-Q
 		Quarter ended June 30, 2024
10-Q
 		Quarter ended March 31, 2024
10-K
 		Fiscal year ended Dec. 31, 2023
10-Q
 		Quarter ended Sept. 30, 2023
10-Q
 		Quarter ended June 30, 2023
10-Q
 		Quarter ended March 31, 2023
10-K
 		Fiscal year ended Dec. 31, 2022
10-Q
 		Quarter ended Sept. 30, 2022
10-Q
 		Quarter ended June 30, 2022
10-Q
 		Quarter ended March 31, 2022
10-K
 		Fiscal year ended Dec. 31, 2021
10-Q
 		Quarter ended Sept. 30, 2021
10-Q
 		Quarter ended June 30, 2021
10-Q
 		Quarter ended March 31, 2021
10-K
 		Fiscal year ended Dec. 31, 2020
10-Q
 		Quarter ended Sept. 30, 2020
10-Q
 		Quarter ended June 30, 2020
10-Q
 		Quarter ended March 31, 2020
10-K
 		Fiscal year ended Dec. 31, 2019
10-Q
 		Quarter ended Sept. 30, 2019
10-Q
 		Quarter ended June 30, 2019
10-Q
 		Quarter ended March 31, 2019
10-K
 		Fiscal year ended Dec. 31, 2018
10-Q
 		Quarter ended Sept. 30, 2018
10-Q
 		Quarter ended June 30, 2018
10-Q
 		Quarter ended March 31, 2018
10-K
 		Fiscal year ended Dec. 31, 2017
10-Q
 		Quarter ended Sept. 30, 2017
10-Q
 		Quarter ended June 30, 2017
10-Q
 		Quarter ended March 31, 2017
10-K
 		Fiscal year ended Dec. 31, 2016
10-Q
 		Quarter ended Sept. 30, 2016
10-Q
 		Quarter ended June 30, 2016
10-Q
 		Quarter ended March 31, 2016
10-K
 		Fiscal year ended Dec. 31, 2015
10-Q
 		Quarter ended Sept. 30, 2015
10-Q
 		Quarter ended June 30, 2015
10-Q
 		Quarter ended March 31, 2015
10-K
 		Fiscal year ended Dec. 31, 2014
10-Q
 		Quarter ended Sept. 30, 2014
10-Q
 		Quarter ended June 30, 2014
10-Q
 		Quarter ended March 31, 2014
10-K
 		Fiscal year ended Dec. 31, 2013
10-Q
 		Quarter ended Sept. 30, 2013
10-Q
 		Quarter ended June 30, 2013
10-Q
 		Quarter ended March 31, 2013
10-K
 		Fiscal year ended Dec. 31, 2012
PROXIES
DEF 14A
 		Filed on March 18, 2024
DEF 14A
 		Filed on March 20, 2023
DEF 14A
 		Filed on March 21, 2022
DEF 14A
 		Filed on March 22, 2021
DEF 14A
 		Filed on March 23, 2020
DEF 14A
 		Filed on March 22, 2019
DEF 14A
 		Filed on March 19, 2018
DEF 14A
 		Filed on March 20, 2017
DEF 14A
 		Filed on March 21, 2016
DEF 14A
 		Filed on March 20, 2015
DEF 14A
 		Filed on March 24, 2014
DEF 14A
 		Filed on March 15, 2013
TABLE OF CONTENTS
Part IItem 1. BusinessItem 1A. Risk FactorsItem 1B. Unresolved Staff CommentsItem 2. PropertiesItem 3. Legal ProceedingsItem 4. Mine Safety DisclosuresPart IIItem 5. Market For Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases Of Equity SecuritiesItem 6. Selected Financial DataItem 7. Management's Discussion and Analysis Of Financial Condition and Results Of OperationsItem 7A. Quantitative and Qualitative Disclosures About Market RiskItem 8. Financial Statements and Supplementary DataNote 1 BackgroundNote 2 Summary Of Significant Accounting PoliciesNote 3 Supplemental Financial InformationNote 4 Earnings Per ShareNote 5 Licensing, Acquisitions and Other ArrangementsNote 6 Collaboration with Janssen Biotech, IncNote 7 Goodwill and Intangible AssetsNote 8 Restructuring PlansNote 9 Debt, Credit Facilities and Commitments and ContingenciesNote 10 Financial Instruments and Fair Value MeasuresNote 11 Post-employment BenefitsNote 12 EquityNote 13 Income TaxesNote 14 Legal Proceedings and ContingenciesNote 15 Segment and Geographic Area InformationNote 16 Quarterly Financial Data (unaudited)Item 9. Changes in and Disagreements with Accountants on Accounting and Financial DisclosureItem 9A. Controls and ProceduresItem 9B. Other InformationPart IIIItem 10. Directors, Executive Officers and Corporate GovernanceItem 11. Executive CompensationItem 12. Security Ownership Of Certain Beneficial Owners and Management and Related Stockholder MattersItem 13. Certain Relationships and Related Transactions, and Director IndependenceItem 14. Principal Accounting Fees and ServicesPart IVItem 15. Exhibits, Financial Statement SchedulesItem 16. Form 10-k Summary

Exhibits

10.22 *Formof AbbVie Inc. Performance Share Award Agreement (incorporated by reference to Exhibit10.25 of the company's Annual Report on Form10-K for the fiscal year ended December31, 2017).** 10.23 *AbbVie Non-Employee Directors' Fee Plan, as amended and restated (incorporated by reference to Exhibit10.26 of the company's Annual Report on Form10-K for the fiscal year ended December31, 2017).** 10.24 *Stemcentrx 2011 Equity Incentive Plan(incorporated by reference to Exhibit4.3 of the Companys Registration Statement on FormS-8 filed on June16, 2016).** 10.25 *Form of AbbVie Inc. Performance-Vested Restricted Stock Unit Agreement (incorporated by reference to Exhibit 10.1 of the companys Quarterly Report on Form 10-Q filed on May 4, 2018).** 10.26 *Form of AbbVie Inc. Performance Share Award Agreement (incorporated by reference to Exhibit 10.2 of the companys Quarterly Report on Form 10-Q filed on May 4, 2018).** 10.27 *Form of AbbVie Inc. Non-Employee Director RSU Agreement (US) (incorporated by reference to Exhibit 10.3 of the companys Quarterly Report on Form 10-Q filed on May 4, 2018).** 10.28 *Form of AbbVie Inc. Non-Qualified Stock Option Agreement (incorporated by reference to Exhibit 10.4 of the companys Quarterly Report on Form 10-Q filed on May 4, 2018).** 10.29 *Form of AbbVie Inc. Non-Employee Director Non-Qualified Stock Option Agreement (incorporated by reference to Exhibit 10.5 of the companys Quarterly Report on Form 10-Q filed on May 4, 2018).** 10.30 *Pharmacyclics,Inc. 2014 Equity Incentive Award Plan (incorporated by reference to Exhibit4.1 of the company's Registration Statement on FormS-8 filed on May27, 2015).** 10.31 *Revolving Credit Agreement, dated as of August31, 2018, among AbbVie, the lenders and other parties party thereto, and JPMorgan Chase Bank, N.A., as administrative agent (incorporated by reference to Exhibit 10.1 of the companys Current Report on Form 8-K filed on September 6, 2018). 10.32 *364-Day Term Loan Credit Agreement, dated as of May17, 2018, among AbbVie, the lenders and other parties party thereto, and Bank of America, N.A., as administrative agent (incorporated by reference to Exhibit10.1 of the companys Current Report on Form8-K filed on May18, 2018). 10.33 *First Amendment to 364-Day Term Loan Credit Agreement, dated as of August31, 2018, among AbbVie, the lenders and other parties party thereto, and Bank of America, N.A., as administrative agent (incorporated by reference to Exhibit 10.2 of the companys Current Report on Form 8-K filed on September 6, 2018). 10.34 *Underwriting Agreement, dated as of May5, 2015, by and among AbbVieInc. and Morgan Stanley&Co.LLC, Barclays CapitalInc., Deutsche Bank SecuritiesInc. and Merrill Lynch, Pierce, Fenner& Smith Incorporated, as representatives of the several other underwriters named therein (incorporated by reference to Exhibit1.1 of the company's Current Report on Form8-K filed on May7, 2015). 10.35 *Underwriting Agreement, dated as of May9, 2016, by and among AbbVie Inc., and Barclays Capital Inc., Deutsche Bank Securities Inc., J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner& Smith Incorporated, as representatives of the several underwriters named in Schedule II thereto (incorporated by reference to Exhibit1.1 of AbbVies Current Report on Form8-K filed on May12, 2016). 10.36 *Underwriting Agreement, dated as of November14, 2016, by and among AbbVie Inc., and Barclays Bank PLC, Deutsche Bank AG, London Branch, J.P. Morgan Securities plc, Merrill Lynch International and Morgan Stanley& Co. International plc, as representatives of the several other underwriters named therein (incorporated by reference to Exhibit1.1 of the company's Current Report on Form8-K filed on November 17, 2016). 10.37 *Underwriting Agreement, dated September13, 2018, by and among AbbVie Inc., Merrill Lynch, Pierce, Fenner& Smith Incorporated, J.P. Morgan Securities LLC, Morgan Stanley& Co. LLC and BNP Paribas Securities Corp. (acting for themselves and as representatives of the several underwriters named therein) (incorporated by reference to Exhibit1.1 of the companys Current Report on Form8-K filed on September18, 2018). 21 Subsidiaries of AbbVieInc. 23 Consent of Independent Registered Public Accounting Firm. 31.1 Certification of Chief Executive Officer Required by Rule13a-14(a) (17 CFR 240.13a-14(a)). 31.2 Certification of Chief Financial Officer Required by Rule13a-14(a) (17 CFR 240.13a-14(a)). 32.1 Certification of Chief Executive Officer Pursuant to 18U.S.C. Section1350, as adopted pursuant to Section906 of the Sarbanes-Oxley Act of 2002. 32.2 Certification of Chief Financial Officer Pursuant to 18U.S.C. Section1350, as adopted pursuant to Section906 of the Sarbanes-Oxley Act of 2002.